Physician profile
William Dalrymple
NPI 1194132811
$568.06
in general payments reported to CMS, 2019-2025
17 companies · $15.25 in 2025
The $15.25 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2021: $265 · 2022: $36.49 · 2023: $79.21 · 2025: $15.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132.83 | 2021-2022 | |
| Novo Nordisk INC | $78.43 | 2019-2025 | Ozempic, Rybelsus |
| Intuitive Surgical, INC. | $61.69 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $36.55 | 2019 | |
| Abbott Laboratories | $34.65 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.15 | 2021 | |
| Merck Sharp & Dohme LLC | $22.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.14 | 2019 | |
| Amarin Pharma, INC. | $18.03 | 2021 | |
| Baxter Healthcare | $17.52 | 2023 | Hillrom - Retinavue 700 Imager |
| Glaxosmithkline, LLC. | $16.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.98 | 2021 | |
| Phadia US INC. | $14.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.13 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coala Life INC | $14.09 | 2021 | |
| Pfizer INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dalrymple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.